Global CRISPR and Cas Genes Market 2023-2030

Description

List of Tables

Title: Global CRISPR and Cas Genes Market Size, Share & Trends Analysis Report by Product Type (Vector-based Cas and DNA-free Cas), by Service Type (Cell Line Engineering, gRNA design, Microbial Gene Editing and DNA Synthesis), by Application (Genome Engineering, Disease Models, Functional Genomics and Other) and by End Users (Biotechnology Companies & Pharmaceutical, Academic and Government Research Institute and CROs),Forecast Period (2023-2030).

Global CRISPR and Cas genes market is anticipated to grow at a CAGR of 13.5% during the Forecast Period (2023-2030). CRISPR-Cas systems are the most widely used genome editing technology in molecular biology laboratories around the globe. The growing adoption of CRISPR-based screens with the improving genomic target is the key factor supporting the growth of the market globally. According to the National Institute of Health (NIH), in April 2020, CRISPR-based screens demonstrated improved versatility, efficacy, and lower off-target effects compared with approaches such as RNAi. Genome-wide CRISPR screen has emerged as a powerful tool for performing large-scale loss-of-function screens, with low noise, high knockout efficiency, and minimal off-target effects. Hence, the market players are also focusing on introducing CRISPR genome-wide knockout library solutions that further bolster the market growth. For instance, in October 2023, Cellecta, Inc. launched genome-wide CRISPR Chicken and Pig Knockout Libraries. Cellecta, Inc. released new pooled, single-module, CRISPR genome-wide knockout libraries for chicken (Gallus gallus) and pig (Sus scrofa). The new libraries allow the study of gene disruptions in a single experiment to enable improved breeding and more.

According to the National Institute of Health (NIH), in December 2022, CRISPR/Cas9 was the predominant tool (85%), followed by TALEN (3.0%). Rice (13.0%), tomato (7.0%), and wheat/barley (3%) were the most studied plants, whereas pig (7.0%), chicken (2.0%), and cow (2.0%) were the main animal species that were investigated.

Segmental Outlook

The global CRISPR and Cas genes market is segmented on the product type, service type, and industry verticals. Based on the product type, the market is sub-segmented into vector-based Cas and DNA-free Cas. Based on the service type, the market is sub-segmented into cell line engineering, gRNA design, microbial gene editing, and DNA synthesis. Based on the application, the market is sub-segmented into genome engineering, disease models, functional genomics, and others. Further, based on end users, the market is sub-segmented into biotechnology companies and pharmaceutical, academic, and government research institutes and CROs. Among the service types, the microbial gene editing sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of CRISPR-Cas9 which can be used to edit genes within microorganisms. This editing process has a wide variety of applications including basic biological research, development of biotechnological products, and treatment of diseases. ICRISPR-Cas systems have also been used for the treatment of other hematologic diseases, such as sickle cell disease (SCD) and hemophilia B (HB). It is not only limited to the treatment of genetic disorders but also it has been found effective for the treatment of metastatic cancer.

The Genome Engineering Sub-Segment is Anticipated to Hold a Considerable Share of the Global CRISPR and CAS genes Market

Among the applications, the genome engineering sub-segment is expected to hold a considerable share of the global CRISPR and Cas genes market. The segmental growth is attributed to the growing influence of CRISPR and Cas technology in the field of correcting pathogenic mutations, searching for essential genes for cancer immunotherapy, and solving key problems in organ xenotransplantation. CRISPR and Cas genes product launch marks dedicated solutions specific to the fast-growing field of editing genomes and modifying gene function. For instance, in June 2021, QIAGEN launched dedicated CRISPR Products for rapid and simplified analysis of gene-editing experiments. The company launched QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.

Regional Outlook

The global CRISPR and Cas genes market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the availability of enhanced individual products such as simple gene knockouts, selective genome cleavage, reduced off-target cutting, genome engineering, and higher specificity. The key market players include Addgene Inc., Danaher Corp., GenScript Biotech, Takara Bio Inc., Thermo Fisher Scientific, Inc., and others.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global CRISPR and Cas Genes Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to increasing government investment in R&D to develop novel treatments is aiding in market expansion Japan and China are anticipated to support the region's growth. For instance, in March 2021, Japanese biotech company Setsuro Tech received a patent for CRISPR-Cas9 technology from Dublin-based ERS Genomics. The company is creating animal and cell models using these advanced technologies. Such initiatives are predicted to enhance CRISPR technology adoption in the region, further contributing towards revenue generation.

Market Players Outlook

The major companies serving the CRISPR and Cas Genes market include: Danaher Corp., GenScript Biotech, Merck KGaA, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Qiagen NV, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2020, Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. collaborated to provide Regeneron with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global CRISPR and Cas genes market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027809

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Danaher Corp.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. GenScript Biotech
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Thermo Fisher Scientific, Inc.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Merck KGaA
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis

4. Market Segmentation

4.1. Global CRISPR and Cas Genes Market by Product Type
- 4.1.1. Vector-based Cas
- 4.1.2. DNA-free Cas
4.2. Global CRISPR and Cas Genes Market by Service Type
- 4.2.1. Cell Line Engineering
- 4.2.2. gRNA Design
- 4.2.3. Microbial Gene Editing
- 4.2.4. DNA Synthesis
4.3. Global CRISPR and Cas Genes Market by Application
- 4.3.1. Genome Engineering
- 4.3.2. Disease Models
- 4.3.3. Functional Genomics
- 4.3.4. Other (Epigenetics and Biomedical)
4.4. Global CRISPR and Cas Genes Market by End Users
- 4.4.1. Biotechnology Companies & Pharmaceutical
- 4.4.2. Academic and Government Research Institute
- 4.4.3. Contract Research Organizations (CROs)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. ACROBiosystems, Inc.
6.2. Agilent Technologies, Inc.
6.3. Bio-Rad Laboratories, Inc.
6.4. Caribou Biosciences, Inc.
6.5. Cell Biolabs, Inc.
6.6. Cellecta, Inc.
6.7. Creative Biogene.
6.8. CRISPR Therapeutics AG
6.9. Editas Medicine, Inc.
6.10. GE Healthcare
6.11. Horizon Discovery Group plc
6.12. Illumina, Inc.
6.13. Inscripta, Inc.
6.14. Integrated DNA Technologies, Inc.
6.15. Lonza Group AG
6.16. New England Biolabs
6.17. OriGene Technologies, Inc.
6.18. Qiagen NV
6.19. Synthego Corp.
6.20. Takara Bio Inc.